(Q51369967)

4 April 2018

title

Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. (English)

1 reference

4 April 2018

0 references

1 reference

1 reference

1 reference

1

1 reference

4 April 2018

Arrigo F. Cicero

2

1 reference

4 April 2018

Angela D'Angelo

3

1 reference

4 April 2018

Elena Fogari

4

1 reference

4 April 2018

Pamela Maffioli

5

1 reference

4 April 2018

publication date

4 August 2011

1 reference

4 April 2018

Journal of Clinical Pharmacy and Therapeutics

published in

1 reference

4 April 2018

volume

37

1 reference

4 April 2018

issue

2

1 reference

4 April 2018

page(s)

187-195

1 reference

4 April 2018

Physical activity/exercise and diabetes

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

The efficacy and safety of sibutramine for weight loss: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Weight management and current options in pharmacotherapy: orlistat and sibutramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Orlistat enhances warfarin effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

The Glycosylation of Hemoglobin: Relevance to Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Determination of total serum insulin (IRI) in insulin-treated diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Use and abuse of HOMA modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Comparison of orlistat treatment and placebo in obese type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Orlistat inhibits dietary cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

The hormone resistin links obesity to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Resistin is an inflammatory marker of atherosclerosis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

RETRACTED: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Medicine. Visfatin: a new adipokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Orlistat for obesity: benefits beyond weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

Molecular Characteristics of Serum Visfatin and Differential Detection by Immunoassays

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01280.X

10.1111/J.1365-2710.2011.01280.X

21 January 2018

Identifiers

DOI

1 reference

4 April 2018

1 reference

4 April 2018